Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/9250
Title: Spectrum of use for the angiotensin-receptor blocking drugs.
Authors: Fabiani, Mark E;Johnston, Colin I
Affiliation: Department of Medicine, University of Melbourne, Austin, Australia.
Issue Date: 1-Oct-1999
Citation: Current Hypertension Reports; 1(5): 394-401
Abstract: The renin-angiotensin system (RAS) plays an important role in regulating blood pressure, and maintaining fluid and electrolyte balance. Angiotensin II is the principal mediator of the RAS and has been implicated in the development of hypertension as well as other forms of cardiovascular and renal disease. Angiotensin II-receptor antagonists are a new class of drugs that inhibit the RAS by selectively blocking the AT(1) receptor. These compounds therefore provide more specific and thorough blockade of the RAS by inhibiting the deleterious actions of angiotensin II at the receptor level, irrespective of how this peptide is formed. The increased specificity of action of angiotensin II-receptor antagonists may also circumvent unwanted side-effects normally associated with angiotensin-converting enzyme (ACE) inhibitors (eg, cough and angioedema) as these agents do not interfere with the metabolism of other peptides (eg, bradykinin, substance P, etc.). There is still some concern with angiotensin II-receptor antagonists and the long-term effects of hyper-stimulation of the unopposed AT(2) receptor that is caused by elevated levels of angiotensin II. However, it appears that stimulation of the AT(2) receptor may actually contribute to the beneficial effects of angiotensin II-receptor antagonists by counteracting the effects mediated by the AT(1) receptor. Angiotensin II-receptor antagonists display great therapeutic promise in the field of cardiovascular medicine and are currently being exploited as new antihypertensive agents. These drugs have demonstrated safety, efficacy, and tolerability; however, morbidity and mortality data are still lacking. Nonetheless, it is likely that angiotensin II-receptor antagonists will become part of the medical arsenal against cardiovascular and renal disease, thus consideration should be given to their future use as first-line antihypertensive agents.
Internal ID Number: 10981096
URI: http://ahro.austin.org.au/austinjspui/handle/1/9250
URL: http://www.ncbi.nlm.nih.gov/pubmed/10981096
Type: Journal Article
Subjects: Angiotensin II.blood
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors.therapeutic use
Blood Pressure.drug effects
Humans
Hypertension.blood.drug therapy.physiopathology
Receptor, Angiotensin, Type 1
Receptor, Angiotensin, Type 2
Receptors, Angiotensin.blood
Renin-Angiotensin System.drug effects.physiology
Treatment Outcome
Vasoconstriction.drug effects
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.